July 6 (SeeNews) - Slovenian drug maker Krka [LJE:KRKG] said on Thursday its preliminary consolidated first-half net profit rose 31% on the year, reaching 91.7 million euro ($104.4 million).
The company generated a consolidated operating profit of 122.4 million euro through June, up 30% year-on-year, with the estimated operating profit before depreciation and amortisation (EBITDA) totalling 176.9 million euro, up 20%, Krka said in a filing with the Ljubljana Stock Exchange.
The Krka Group sold 655 million euro worth of products and services in the first half of 2017, up 8.5% on the year, achieving its best half-year sales result to date.
Sales in markets outside Slovenia totalled 612.1 million euro, which represents a solid 93% of the group's total sales.
The largest sales region was East Europe, where Krka generated 214 million euro, or 32.7% of overall sales. Year-on-year sales there increased by 22%, which is the highest absolute and relative sales growth among all Krka sales regions.
The second largest region in terms of sales was Central Europe, where Krka generated 154.4 million euro (up 9%), which is 23.6% of total sales. Product sales in West Europe fell 5% on the year to 143.2 million euro in the six-month period, which represents 21.9% of Krka Group sales.
In South-East Europe Krka sales amounted to 79.8 million euro, a 4% year-on-year increase, representing 12.2% of total sales. Sales on the domestic market were up 4% to 43 million euro, or 6.5% of total sales, while product sales in the Overseas Markets region totalled 20.7 million euro (12% increase), which represents 3.1% of overall sales.
At the end of June, the Krka Group employed 10,842 people, with 54% of them in subsidiaries and representative offices outside Slovenia.
($=0.878264 euro)